Cargando…

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review

Detalles Bibliográficos
Autores principales:	Elyan, Benjamin M.P., Rankin, Stephen, Jones, Rob, Lang, Ninian N., Mark, Patrick B., Lees, Jennifer S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363559/ https://www.ncbi.nlm.nih.gov/pubmed/37492115 http://dx.doi.org/10.1016/j.xkme.2023.100672

Ejemplares similares

A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes
por: Lees, Jennifer S, et al.
Publicado: (2022)

The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes
por: Lees, Jennifer S, et al.
Publicado: (2022)

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors
por: Touyz, Rhian M., et al.
Publicado: (2019)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Sharma, Revati, et al.
Publicado: (2021)

Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition
por: Shijubou, Naoki, et al.
Publicado: (2022)

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity
por: Moss, Emily M., et al.
Publicado: (2022)

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
por: Bagegni, Nusayba A., et al.
Publicado: (2022)

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor
por: Harada, Mirii, et al.
Publicado: (2023)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
por: Stagnetto, Margot, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
por: Peng, Lijun, et al.
Publicado: (2022)

Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
por: Johnson, Douglas B., et al.
Publicado: (2023)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond
por: Tinawi, Mohammad, et al.
Publicado: (2020)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Cardiotoxic effects of angiogenesis inhibitors
por: Dobbin, Stephen J.H., et al.
Publicado: (2021)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Checkpoint Inhibitors and Hepatotoxicity
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
por: Hayashi, Fuuka, et al.
Publicado: (2022)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Immune Checkpoint Inhibitor–Associated Sarcoidosis Reaction in the Kidney: Case Report
por: Charkviani, Mariam, et al.
Publicado: (2023)

Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Publicado: (2023)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

Combination Checkpoint Inhibitor-Induced Hemorrhagic Gastritis
por: Bazarbashi, Ahmad Najdat, et al.
Publicado: (2020)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors
por: Bestion, Eloïne, et al.
Publicado: (2023)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pcuenhn75a97im5hlob9ie5aud